Why did MDG1.F stock spike pre-market

MDG1.F stock spiked pre-market due to thin liquidity and concentrated buying while Medigene remains in asset liquidation. Volume jumped to **68,620** versus an average **13,127**, causing a rapid price move rather than a change in operations.

What is Meyka AI’s view on MDG1.F stock

Meyka AI gives MDG1.F a **C+** score (58.47) and labels it **HOLD**. The grade weighs benchmark and sector comparisons, growth metrics and forecasts. This is informational and not investment advice.

What short-term price target exists for MDG1.F stock

Meyka AI's forecast model projects a 12-month base target of **EUR 0.090** for MDG1.F stock, implying **+63.64%** from the current **EUR 0.055**. Forecasts are model-based projections and not guarantees.

What are the main risks for MDG1.F stock investors

Key risks for MDG1.F stock include extreme volatility from low liquidity, possible dilution during liquidation, and negative surprises on asset-sale timing. Small market cap stocks can swing widely on single trades.

DE Stocks

MDG1.F stock rises 58% pre-market on XETRA: liquidity spike drives rally

ByHuzaifa Zahoor January 29, 2026January 29, 2026

MDG1.F stock led pre-market gainers on 29 Jan 2026 after a sharp volume surge. The XETRA-traded Medigene AG share climbed about 58.29% to EUR 0.055 in early trading on Germany’s exchange. Volume hit 68,620 versus an average of 13,127, a 5.23x relative volume move. The move reflects thin liquidity, asset liquidation news and a low market cap of EUR 816,463. We examine drivers, ratios, risks and a short-term forecast for investors watching the top gainer in the Healthcare sector